Recombinant Anti-IL13 x Anti-IL17 Bispecific Antibody (scIgG) (SCIGG-172)

Recombinant Anti-IL13 x Anti-IL17 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-IL13 and anti-IL17 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can bind and inactivate two ligands simultaneously. It is designed for the research of Asthma therapy.

Datasheet INQUIRY

Specifications

Targets

IL13 & IL17

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Asthma

Targets

Target 1

IL13

Gene ID

3596

UniProt ID

P35225

Alternative Names

IL13; interleukin 13; P600; IL-13; interleukin-13

Target 2

IL17

Gene ID

3605

UniProt ID

Q16552

Alternative Names

IL17A; interleukin 17A; IL17; CTLA8; IL-17; IL-17A; interleukin-17A; CTLA-8; cytotoxic T-lymphocyte-associated antigen 8; cytotoxic T-lymphocyte-associated protein 8; interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8)

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-IL13 x Anti-IL17 Bispecific Antibody (scIgG) (SCIGG-172). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-IL13 x Anti-IL17 Bispecific Antibody (scIgG) (CAT#: SCIGG-172)

Specifications

Targets

Customer Reviews and Q&As